Published • loading... • Updated
Amygdala Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for ANS
Summary by The AI Journal
1 Articles
1 Articles
Amygdala Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for ANS
ANS-858 is being developed to reduce pathological craving associated with alcohol and other substance use disorders. Amygdala’s ALDH2 inhibitor platform offers additional therapeutic opportunities in binge eating, obesity, and precision oncology. PALO ALTO, Calif., Aug. 18, 2026 /PRNewswire/ — Amygdala Neurosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) app…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
